STOCKHOLM, April 8, 2019 /PRNewswire/ -- Moberg Pharma AB
(OMX: MOB) has a nimbler organization following the divestment of
its OTC business, and intends to adapt the leadership accordingly.
The Board of Directors and Nomination Committee have therefore
proposed the appointment of Anna
Ljung as the new CEO of Moberg Pharma, while current CEO
Peter Wolpert will transition to a
role as Executive Chairman of the Board of Directors. At the same
time, a new management team is proposed based on the company's new
situation and focus. The organizational changes are contingent on
the approval of the Annual General Meeting (AGM) and the Board of
Directors elected by the AGM.
The divestment of the OTC business on March 29, 2019 represents a significant change
for Moberg Pharma in terms of both strategic direction and
organization. Approximately half of the previous employees remain
in the company, focusing on the development and commercialization
of the drug project MOB-015, while the rest have followed the OTC
business to the new owners. The new conditions motivate a change in
leadership to a new, smaller management team appropriate for the
challenges ahead.
According to the proposal of the Board of Directors and
Nomination Committee, Anna Ljung
will be appointed as the new CEO of Moberg Pharma, while current
CEO Peter Wolpert will transition to
a role as Executive Chairman of the Board. As proposed, the new
management team will consist of four individuals: Anna Ljung (CEO), Torbjörn Wärnheim (Deputy CEO
and Senior Vice President R&D), Sarah Hellerfeldt (CFO) and
Annica Magnusson (Senior Director
Regulatory Affairs). In addition, the company has engaged Dr.
Amir Tavakkol as Senior Advisor
R&D, bringing unique experience in the development and
registration of nail fungus medications in the US.
"I look forward to the opportunity to transition to a role as
Executive Chairman while remaining close to the new management.
After 13 intensive years as CEO of Moberg Pharma, it is important
for me to be able to spend more time with my family, as well as
continuing to contribute in a valuable way according to the
company's new needs," says Peter
Wolpert, CEO of Moberg Pharma AB.
The organizational changes are expected to be effective from
May 16, 2019 and are contingent on
the approval of the incoming Board of Directors elected at the AGM
on May 15, 2019, based on the
Nomination Committee's proposal; see separate press release. As
proposed, the company's new management will be as follows:
- Current CEO Peter Wolpert
is nominated as Executive Chairman with a focus on
commercialization in the US, business development and further
development of investor relations, all while remaining close to the
new management.
- Current CFO Anna Ljung is
nominated as the new CEO of Moberg Pharma. Anna Ljung has been a driving force for Moberg
Pharma since 2006 when the company was founded and she became the
CFO. Anna Ljung has more than 15
years of experience from the pharmaceutical industry, previously
having been the CFO at Athera Biotechnologies AB and Lipopeptide AB
as well as independent consultant within technology licensing.
- Torbjörn Wärnheim is nominated as Deputy CEO and Senior
Vice President R&D. Torbjörn Wärnheim has been employed by the
company since 2014 and has had a key role in the organization as
Vice President Pharmaceutical Innovation and Development.
- Current finance manager Sarah Hellerfelt is nominated as
the new CFO. Sarah Hellerfelt has been employed since 2017 and has
played a key role on the company's finance team. Current VP Finance
Mark Beveridge will be leaving the
management team but remains a consultant to the company on
financial issues.
- Dr. Amir Tavakkol has been
engaged by the company as Senior Advisor R&D. Dr. Tavakkol
brings 20 years of unique experience in the development and
registration of nail fungus drugs in the US from senior R&D
positions at Novartis, Schering-Plough, Topica Pharmaceuticals and
Viamet. He has contributed to the development and registration of
drugs such as Lamisil, Kerydin, Luzu and VT-1161. Dr. Shaw
Sooroshian will be leaving the management team and his role as
Chief Medical Officer of Moberg Pharma but will remain as a
consultant to the company for a certain period.
CONTACT:
For additional information, please contact:
Peter Wolpert, CEO, phone:
+46-707-35-7135, e-mail: peter.wolpert@mobergpharma.se
Anna Ljung, CFO, phone:
+46-707-66-6030, e-mail: anna.ljung@mobergpharma.se
About this information
This is information that Moberg Pharma AB (publ) is obliged to
make public pursuant to the EU Market Abuse Regulation (MAR). The
information was submitted for publication, through the contact
persons set out above at 16.00 CET on April
8, 2019.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/moberg-pharma/r/proposed-management-changes-at-moberg-pharma,c2783219
The following files are available for download:
https://mb.cision.com/Main/1662/2783219/1021676.pdf
|
Proposed management
changes at Moberg Pharma
|
View original
content:http://www.prnewswire.com/news-releases/proposed-management-changes-at-moberg-pharma-300826109.html
SOURCE Moberg Pharma